stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Current ratio
Cogent Biosciences, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 13.6×, down 0.7× from fiscal 2025 (14.2×). Over the past ten years it has ranged from 3.1× (fiscal 2019) to 18.7× (fiscal 2020); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 5.0× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 14.2× | 167.49% |
| FY2024 | 5.3× | (24.99%) |
| FY2023 | 7.1× | (28.11%) |
| FY2022 | 9.9× | (24.30%) |
| FY2021 | 13.0× | (30.30%) |
| FY2020 | 18.7× | 510.47% |
| FY2019 | 3.1× | (5.64%) |
| FY2018 | 3.2× | (14.26%) |
| FY2017 | 3.8× | (52.55%) |
| FY2016 | 8.0× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 13.6× | (10.35%) |
| Mar 2026 | 15.1× | 6.36% |
| Dec 2025 | 14.2× | 123.05% |
| Sep 2025 | 6.4× | 52.17% |
| 32 more quarters | Free account |
Against its own ten years
Low 3.1×
High 18.7×
Ten-year median
7.5×
Current reading's percentile
90
Current ratio against peers
| Company | Current ratio |
|---|---|
| MANE Veradermics Incorporated compare | 70.5× |
| DNTH Dianthus Therapeutics, Inc. compare | 30.0× |
| CRSP CRISPR Therapeutics AG compare | 16.2× |
| COGT Cogent Biosciences, Inc. | 13.6× |
| ERAS Erasca, Inc. compare | 8.3× |
| SRRK Scholar Rock Holding Corporation compare | 7.0× |
| PTCT PTC Therapeutics, Inc. compare | 3.3× |
| TVTX Travere Therapeutics, Inc. compare | 3.0× |
| KOD Kodiak Sciences Inc. compare | 2.5× |
| Biotechnology industry median | 5.0× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement